1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Available at https://www.cdc.gov/diabetes/data/statistics-report/index.html. Last accessed February 4, 2022.
2. Cornell S, Dorsey VJ. Diabetes pharmacotherapy in 2012: considerations in medication selection. Postgrad Med. 2012;124(4):84-94.
3. Centers for Disease Control and Prevention. Diabetes Report Card 2019. Available at https://www.cdc.gov/diabetes/library/reports/reportcard.html. Last accessed February 4, 2022.
4. Grandy S, Fox DM. Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health Qual Life Outcomes. 2012;10(1):99.
5. Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6-12.
6. Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Prev Med. 2007;45(5):348-352.
7. Centers for Disease Control and Prevention. United States Diabetes Surveillance System. Diagnosed Diabetes. Available at https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html#. Last accessed February 4, 2022.
8. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the U.S. adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.
9. Lin J, Thompson TJ, Chnge YJ, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018;16:9.
10. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 27 million participants. Lancet. 2011;378(9785):31-40.
11. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-79.
12. National Center for Health Statistics. Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, Trends 1960–1962 Through 2017-2018. Available at https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm#. Last accessed February 4, 2022.
13. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284-2291.
14. Drab SR. Recognizing the rising impact of diabetes in seniors and implications for its management. Consult Pharm. 2009;24(Suppl B):5-10.
15. Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3(1):60-63.
16. Zhang Q, Wang Y, Huang ES. Changes in racial/ethnic disparities in the prevalence of type 2 diabetes by obesity level among U.S. adults. Ethn Health. 2009;14(5):439-457.
17. Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(Suppl 12):S5-S14.
18. American Diabetes Association. Pathogenesis. In: Burant CF (ed). Medical Management of Type 2 Diabetes. 7th ed. Alexandria, VA: American Diabetes Association: 2012;19-28.
19. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121.
20. Campbell RK. Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc. 2009;49(Suppl 1):S10-S15.
21. Vimaleswaran KS, Loos RJ. Progress in the genetics of common obesity and type 2 diabetes. Expert Rev Mol Med. 2010;12:e7.
22. Triplitt C. Examining the mechanisms of glucose regulation. Am J Manag Care. 2012;18(1 Suppl):S4-S10.
23. Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab. 2009;35(2):77-84.
24. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218.
25. Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1-2):127-136.
26. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab. 2008;10(9):699-718.
27. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul Pharmacol. 2012;57(2-4):91-97.
28. American Diabetes Association. Standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl 1):S1-S259.
29. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26(1):107-139.
30. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2018;41(12):2669-2701.
31. AACE Task Force for Developing a Diabetes Comprehensive Care Plan Writing Committee. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan, 2015. Endocr Pract. 2015;21(Suppl 1):1-87.
32. Qaseem A, Barry MJ, Humphrey LL, Forciea MA. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(4):279-290.
33. U.S. Preventive Services Task Force. Behavioral counseling in primary care to promote a healthy diet: recommendations and rationale. Am J Prev Med. 2003;24(1):93-100.
34. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002;4(6):407-414.
35. U.S. Department of Health and Human Services and Department of Agriculture. Dietary Guidelines for Americans, 2020–2025. 9th ed. Washington, DC: U.S. Department of Health and Human Services; 2020.
36. Morris SF, Wylie-Rosett J. Medical nutrition therapy: a key to diabetes management and prevention. Clinical Diabetes. 2010;28(1):12-18.
37. Medicare. Your Medicare Coverage: Nutrition Therapy Services. Available at https://www.medicare.gov/coverage/nutrition-therapy-services. Last accessed February 4, 2022.
38. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and type 2 diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079.
39. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423-1434.
40. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221-228.
41. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-1437.
42. U.S. Food and Drug Administration. FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function. Available at https://www.fda.gov/media/96771/download. Last accessed February 4, 2022.
43. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
44. Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial.Lancet. 2005;366(9493):1279-1289.
45. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media cardiovascular system thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572-2581.
46. Lexicomp Online. Available at https://online.lexi.com/lco/action/login. Last accessed February 4, 2022.
47. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2012;170(14):1191-1201.
48. Tucker ME. FDA Lifts Final Regulatory Restrictions on Rosiglitazone. Available at https://www.medscape.com/viewarticle/856056. Last accessed February 4, 2022.
49. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-922.
50. U.S. Food and Drug Administration. FDA Approves Invokana to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023858/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Last accessed February 4, 2022.
51. U.S. Food and Drug Administration. FDA Approves Farxiga to Treat Type 2 Diabetes. Available at https://wayback.archive-it.org/7993/20170112023850/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm380829.htm. Last accessed February 4, 2022.
52. U.S. Food and Drug Administration. FDA Approves Jardiance to Reduce Cardiovascular Death in Adults With Type 2 Diabetes. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-jardiance-reduce-cardiovascular-death-adults-type-2-diabetes. Last accessed February 4, 2022.
53. U.S. Food and Drug Administration. SGLT2 Inhibitors: Drug Safety Communication – FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Last accessed February 4, 2022.
54. U.S. Food and Drug Administration. FDA Confirms Increased Risk of Leg and Foot Amputations with the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR). Available at https://www.fda.gov/media/104870/download. Last accessed February 4, 2022.
55. U.S. Food and Drug Administration. FDA Warns about Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes. Last accessed February 4, 2022.
56. U.S. Food and Drug Administration. Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections: 3-19-2020 Update. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Last accessed February 4, 2022.
57. Adeghate E, Kalász H. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med Chem J. 2011;5(Suppl 2):78-81.
58. Ali MK, McKeever Bullard K, Imperatore G, Barker L, Gregg EW. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes—National Health and Nutrition Examination Survey, United States, 2007–2010. MMWR. 2012;61(2):32-37.
59. Rodbard HW, Trence DL, Mechanick JI. Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent studies of intensive glycemic control. Endocr Pract. 2008;14(6):791-795.
60. Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168:569-576.
61. PR Newswire. American Diabetes Association® Deeply Concerned About New Guidance from American College of Physicians Regarding Blood Glucose Targets for People with Type 2 Diabetes. Available at https://www.prnewswire.com/news-releases/american-diabetes-association-deeply-concerned-about-new-guidance-from-american-college-of-physicians-regarding-blood-glucose-targets-for-people-with-type-2-diabetes-300611159.html. Last accessed February 4, 2022.
62. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
63. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.
64. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
65. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.N Engl J Med. 2003;348(23):224-303.
66. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
67. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
68. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21-B29.
69. Gaede P, Vedol P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
70. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
71. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
72. ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.
73. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
74. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
75. Mattila TK, de Boer A. Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus. Drugs. 2010;70(17):2229-2245.
76. Marso SP, Kennedy KF, House JA, McGuire DK. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res. 2010;7(2):119-130.
77. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6869.
78. Triplitt C. Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough? Consult Pharm. 2010;25(Suppl B):19-27.
79. Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ. 2011;20(10):647-654.
80. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3): 314-322.
81. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.
82. Salas M, Hughes D, Zuluaga A, Vardeva K, Lebmeier M. Cost of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health. 2009;12(6):915-922.
83. Ratanawongsa N, Crosson JC, Schillinger D, Karter AJ, Saha CK, Marrero DG. Getting under the skin of clinical inertia in insulin initiation: the Translating Research Into Action for Diabetes (TRIAD) Insulin Starts Project. Diabetes Educ. 2012;38(1):94-100.
84. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 2005;27(7):1064-1073.
85. Bundrick Harrison L, Lingvay I. Appointment and medication non-adherence is associated with increased mortality in insulin-treated type 2 diabetes. Evid Based Med. 2013;18(3):112-113.
87. Nau DP. Recommendations for improving adherence to type 2 diabetes mellitus therapy—focus on optimizing oral and non-insulin therapies. Am J Manag Care. 2012;18(Suppl 3):S49-S54.
88. Alvarez Guisasola F, Tofé-Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10(Suppl 1):25-32.
89. Vanderpoel DR, Hussein MA, Watson-Heidari T, Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther. 2004;26(12):2066-2075.
90. Thayer S, Arondekar B, Harley C, Darkow TE. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea. Ann Pharmacother. 2010;44(5):791-799.
91. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-1168.
92. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4):338-342.
93. Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy—focus on optimizing insulin-based therapy. Am J Manag Care. 2012;18(Suppl):S55-S61.
94. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725.
95. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.
96. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control. Manag Care. 2009;18(7):47-53.
97. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4(4):203-207.
98. Siminerio LM. Approaches to help people with diabetes overcome barriers for improved health outcomes. Diabetes Educ. 2008;34(Suppl 1):18S-24S.
99. Hajos TR, Polonsky WH, Twisk JW, Dain MP, Snoek FJ. Do physicians understand type 2 diabetes patients' perceptions of seriousness; the emotional impact and needs for care improvement? A cross-national survey. Patient Educ Couns. 2011;85(2):258-263.
100. Beck RS, Daughtridge R, Sloane PD. Physician-patient communication in the primary care office: a systematic review. J Am Board Fam Pract. 2002;15(1):25-38.
101. Office of Minority Health. Think Cultural Health. Available at https://www.minorityhealth.hhs.gov/Assets/PDF/TCH%20Resource%20Library_CLAS%20CLC%20CH.pdf. Last accessed February 4, 2022.
102. Paez K, Allen JK, Beach MC, Carson KA, Cooper LA. Physician cultural competence and patient ratings of the patient-physician relationship. J Gen Intern Med. 2009;24(4):495-498.
103. Powers BJ, Trinh JV, Bosworth HB. Can this patient read and understand written health information? JAMA. 2010;304(1):76-84.
104. U.S. Census Bureau. Selected Social Characteristics in the United States: 2019. Available at https://data.census.gov/cedsci/table?d=ACS%205-Year%20Estimates%20Data%20Profiles&table=DP02&tid=ACSDP5Y2019.DP02. Last accessed February 4, 2022.
105. Karliner LS, Napoles-Springer AM, Schillinger D, Bibbins-Domingo K, Pérez-Stable EJ. Identification of limited English proficient patients in clinical care. J Gen Intern Med. 2008;23(10):1555-1560.
106. Sevilla Mátir JF, Willis DR. Using bilingual staff members as interpreters. Fam Pract Manag. 2004;11(7):34-36.
107. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care: perspectives of Chinese and Vietnamese immigrants. J Gen Intern Med. 2003;18(1):44-52.
108. Flores G. Language barriers to health care in the United States. N Engl J Med. 2006;355(3):229-231.
109. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255-299.
110. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.
111. Surbone A. Family, autonomy, and cultural differences. In: Perry M (ed). American Society of Clinical Oncology 2006 Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2006: 156-159.
112. Chao MT, Wade C, Kronenberg F. Disclosure of complementary and alternative medicine to conventional medical providers: variation by race/ethnicity and type of CAM. J Natl Med Assoc. 2008;100(11):1341-1349.
113. Graham RE, Ahn AC, Davis RB, O'Connor BB, Eisenberg DM, Phillips RS. Use of complementary and alternative medical therapies among racial and ethnic minority adults: results from the 2002 National Health Interview Survey. J Natl Med Assoc. 2005;97(4):535-545.
114. Committee on Health Literacy, Board on Neuroscience and Behavioral Health. Health Literacy: A Prescription to End Confusion. Washington, DC: The National Academies Press; 2004.
115. Kutner M, Greenberg E, Jin,Y, Paulsen C, White S. The Health Literacy of America's Adults: Results from the 2003 National Assessment of Adult Literacy. Washington, DC: National Center for Education Statistics; 2006.
116. Paasche-Orlow MK, Parker RM, Gazmararian JA, Nielsen-Bohlman LT, Rudd RR. The prevalence of limited health literacy. J Gen Intern Med. 2005;20(2):175-184.
117. Shah LC, West P, Bremmeyr K, Savoy-Moore RT. Health literacy instrument in family medicine: the "newest vital sign" ease of use and correlates. J Am Board Fam Med. 2010;23(2):195-203.
118. Jeppesen KM, Coyle JD, Miser WF. Screening questions to predict limited health literacy: a cross-sectional study of patients with diabetes mellitus. Ann Fam Med. 2009;7(1):24-31.
119. Weiss BD, Mays MZ, Martz W, et al. Quick assessment of literacy in primary care: the newest vital sign. Ann Fam Med. 2005;3(6):514-522.
120. Vervloet M, van Dijk L, Santen-Reestman J, van Vlijmen B, Bouvy ML, de Bakker DH. Improving medication adherence in diabetes type 2 patients through real time medication monitoring: a randomized controlled trial to evaluate the effect of monitoring patients' medication use combined with short message service (SMS) reminders. BMC Health Serv Res. 2011;11:5.
1. Redmon B, Caccamo D, Flavin P, et al. Diagnosis and Management of Type 2 Diabetes Mellitus in Adults. Bloomington, MN: Institute for Clinical Systems Improvement; 2014. Available at https://www.icsi.org/wp-content/uploads/2019/02/Diabetes.pdf. Last accessed February 11, 2022.
2. Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020;173(10):813-821. Available at https://www.acpjournals.org/doi/10.7326/M20-2470. Last accessed February 11, 2022.
Mention of commercial products does not indicate endorsement.